Bioxcel therapeutics, inc. (BTAI)
Income statement / Yearly
Dec'19Dec'18Dec'17
Operating costs and expenses
Research and development

25,797

14,558

2,690

General and administrative

7,804

5,404

1,847

Total operating expenses

33,601

19,962

4,537

Loss from operations

-33,601

-19,962

-4,537

Other income
Dividend and interest income, net

633

692

-2

Net loss

-32,968

-19,270

-4,539

Net loss per share attributable to common stockholders basic and diluted

-2.02

-1.32

-0.47

Weighted average shares outstanding - basic and diluted

16,289

14,571

9,685